Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 13Opdivo

02 4Opdivo

03 2Opdualag

PharmaCompass

01

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 6,992

2019 Revenue in Millions : 7,204

Growth (%) : -3

blank

02

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 907

2019 Revenue in Millions : 827

Growth (%) : 10

blank

03

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 7,523

2020 Revenue in Millions : 6,992

Growth (%) : 8

blank

04

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 908

2020 Revenue in Millions : 870

Growth (%) : 12

blank

05

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 8,249

2021 Revenue in Millions : 7,523

Growth (%) : 10

blank

06

Brand Name : Opdualag

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdualag

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 252

2021 Revenue in Millions : 0

Growth (%) : New Launch in 2022

blank

07

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,050

2021 Revenue in Millions : 908

Growth (%) : 16

blank

08

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 9,009

2022 Revenue in Millions : 8,249

Growth (%) : 9

blank

09

Brand Name : Opdualag

Nivolumab/Relatlimab-rmbw

arrow
Antibody Engineering
Not Confirmed

10

Brand Name : Opdivo

Nivolumab

arrow
Antibody Engineering
Not Confirmed

Brand Name : Opdivo

arrow
Antibody Engineering
Not Confirmed

Nivolumab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,001

2022 Revenue in Millions : 1,050

Growth (%) : 8

blank